<DOC>
	<DOCNO>NCT00225420</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , docetaxel , work different way stop growth tumor cell , either kill cell stop dividing . Androgens cause growth prostate cancer cell . Antihormone therapy , leuprolide , may lessen amount androgen make body . Radiation therapy use high energy x-ray kill tumor cell . Giving docetaxel together androgen ablation therapy external-beam radiation therapy may kill tumor cell . PURPOSE : This phase I/II trial study side effect best dose docetaxel give together androgen ablation therapy external-beam radiation therapy see well work treat patient high-risk localized prostate cancer .</brief_summary>
	<brief_title>Docetaxel , Androgen Ablation Therapy , External-Beam Radiation Therapy Treating Patients With High-Risk Localized Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine dose-limiting toxicity maximum tolerate dose docetaxel administer combination androgen ablation therapy adaptive external-beam radiotherapy patient high-risk localized adenocarcinoma prostate . Secondary - Determine 2-year biochemical progression-free survival patient treat regimen . OUTLINE : This multicenter , open-label , dose-escalation study docetaxel . - Androgen ablation therapy : Patients receive leuprolide acetate luteinizing hormone-releasing hormone agonist begin 2-3 month prior start chemoradiotherapy continue 2 year . - Chemoradiotherapy : Patients receive docetaxel IV 1 hour day 1 high-dose external-beam radiotherapy day 1-5 . Treatment repeat every 7 day 8 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos docetaxel maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . After completion study treatment , patient follow every 3 month .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma prostate Highrisk localize disease , meet 1 follow criterion : T3 T4 T12 Gleason score 810 T12 Gleason score 7 AND PSA ≥ 10 ng/mL T12 Gleason score AND PSA ≥ 20 ng/mL No evidence metastatic disease chest xray , bone scan , CT scan abdomen pelvis PATIENT CHARACTERISTICS : ECOG performance status 01 Life expectancy ≥ 10 year Absolute neutrophil count ≥ 1,500/mm^3 Hemoglobin ≥ 8.0 g/dL Platelet count ≥ 100,000/mm^3 Bilirubin ≤ 1.2 mg/dL Creatinine ≤ 1.5 time upper limit normal ( ULN ) AST ALT ≤ 1.5 time ULN Alkaline phosphatase ≤ 2.5 time ULN Fertile patient must use effective contraception ≥ 3 month completion study therapy No peripheral neuropathy &gt; grade 1 No myocardial infarction significant change anginal pattern within past year No New York Heart Association class IIIV congestive heart failure No history severe hypersensitivity reaction docetaxel drug formulate polysorbate 80 No invasive malignancy within past 5 year except carcinoma situ nonmelanoma skin cancer No concurrent uncontrolled illness , psychiatric condition , condition would preclude study treatment PRIOR CONCURRENT THERAPY : No prior pelvic prostate radiotherapy prostate cancer No prior chemotherapy prostate cancer Prior androgen ablation therapy luteinizing hormonereleasing hormone agonist allow provide study treatment start within 3 month initiation androgen ablation therapy No concurrent investigational agent Concurrent anticoagulation stable dose warfarin low molecular weight heparin allow</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage I prostate cancer</keyword>
	<keyword>stage II prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
</DOC>